Shannon L. Devers - 15 Oct 2025 Form 4 Insider Report for IONIS PHARMACEUTICALS INC (IONS)

Role
EVP, Chief Human Resources Ofc
Signature
By: Patrick R. O'Neil, attorney-in-fact For: Shannon L. Devers
Issuer symbol
IONS
Transactions as of
15 Oct 2025
Net transactions value
-$239,578
Form type
4
Filing time
16 Oct 2025, 20:16:08 UTC
Previous filing
04 Sep 2025
Next filing
28 Nov 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Devers Shannon L. EVP, Chief Human Resources Ofc 2855 GAZELLE COURT, CARLSBAD By: Patrick R. O'Neil, attorney-in-fact For: Shannon L. Devers 16 Oct 2025 0002037721

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IONS Common Stock Options Exercise $291,060 +6,000 +38% $48.51 21,937 15 Oct 2025 Direct
transaction IONS Common Stock Sale $437,654 -6,000 -27% $72.94 15,937 15 Oct 2025 Direct F1, F2
transaction IONS Common Stock Options Exercise $0 +2,820 +18% $0.000000 18,757 15 Oct 2025 Direct F3
transaction IONS Common Stock Sale $92,984 -1,263 -6.7% $73.62 17,494 16 Oct 2025 Direct F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IONS Non-Qualified Stock Option (right to buy) Options Exercise $0 -6,000 -100% $0.000000 0 15 Oct 2025 Common Stock 6,000 $48.51 Direct
transaction IONS Restricted Stock Unit Options Exercise $0 -2,820 -4.5% $0.000000 60,406 15 Oct 2025 Common Stock 2,820 $0.000000 Direct F5, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on September 3, 2024.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.775 to $73.04 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.
F3 Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award.
F4 The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice.
F5 Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.
F6 Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.